Literature DB >> 33693305

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges.

Alfons A den Broeder1, Nathan den Broeder1, Lise M Verhoef1.   

Abstract

Entities:  

Year:  2021        PMID： 33693305      PMCID： PMC7931796          DOI： 10.1093/rap/rkab007

Source DB:  PubMed          Journal:  Rheumatol Adv Pract        ISSN： 2514-1775


× No keyword cloud information.
  7 in total

1.  Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Authors:  M J Leandro; J C W Edwards; G Cambridge
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 2.  Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.

Authors:  Simon Tarp; Daniel Eric Furst; Maarten Boers; George Luta; Henning Bliddal; Ulrik Tarp; Karsten Heller Asmussen; Birgitte Brock; Anna Dossing; Tanja Schjødt Jørgensen; Steffen Thirstrup; Robin Christensen
Journal:  Rheumatology (Oxford)       Date:  2017-03-01       Impact factor: 7.580

Review 3.  Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.

Authors:  Markus Bredemeier; Guilherme G Campos; Fernando K de Oliveira
Journal:  Clin Rheumatol       Date:  2015-06-12       Impact factor: 2.980

4.  Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.

Authors:  Julien Henry; Jacques-Eric Gottenberg; Stéphanie Rouanet; Stephan Pavy; Jeremie Sellam; Florence Tubach; Rakiba Belkhir; Xavier Mariette; Raphaèle Seror
Journal:  Rheumatology (Oxford)       Date:  2018-03-01       Impact factor: 7.580

5.  Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

Authors:  Joseph R Berger; Vineeta Malik; Stuart Lacey; Paul Brunetta; Patricia B Lehane
Journal:  J Neurovirol       Date:  2018-03-05       Impact factor: 2.643

6.  Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.

Authors:  Hendrik Schulze-Koops; Klaus Krueger; Inka Vallbracht; Rebecca Hasseli; Alla Skapenko
Journal:  Ann Rheum Dis       Date:  2020-06-26       Impact factor: 19.103

7.  Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact.

Authors:  Parvathypriya Chandramohan; Avinash Jain; Glindow Antony; Narayanan Krishnan; Padmanabha Shenoy
Journal:  Rheumatol Adv Pract       Date:  2021-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.